jkahn@php.ucsf.edu
(415) 476-4082, ext. 408 (voice)
(415) 476-6953 (fax)

Box 0874, UCSF; San Francisco, CA 94143-0874

University of California at Berkeley, A.B., 1974, American History
University of California San Francisco, Medical School, M.D., 1982-1985, Medicine
Johns Hopkins University, 1982-1984, Intern and Junior Medical Resident
University of California San Francisco, 1984-1985, Senior Medical Resident
Clinical Epidemiology Program, UCSF, 1985-1986, Fellowship in Clinical Epidemiology
Cancer Research Institute, Hematology and Oncology, UCSF, 1987, Fellowship

Kahn J, Lagakos S, Richman D, et al. A controlled trial comparing continued zidovudine with didanosine in human Immunodeficiency virus infection. N Engl J Med. 1992: 327: 581-7.

Kahn J, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman R, Dekker C, Steimer KS Chernoff D. Clinical and Immunologic responses to HIV-1SF2 gp 120 subunit vaccine combined with MF59 adjuvant with or without MTP-PE in non-HIV-infected human volunteers. J Inf. Dis. 1994:170:1288-91.

Kahn J, Steimer KS, Baenziger J, Duliege AM, Mark Feinberg, Tarek Elbek, Dekker C, Chernoff D and Sinagil F. Brief report: Clinical immunologic and virologic observations related to HIV-1 infection in a volunteer participating in an HIV-1 vaccine clinical trial 1995 J Inf. Dis; 171:1343-7.

Richard T. D'Aquila, Johnson VA, Wells SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn J, and Richman DD. Zidovudine Resistance and Human Immunodeficiency Virus Type-1 disease progression during antiretroviral therapy. Annals Internal Medicine. 1995; 122:401-8.

Japour AJ, Wells S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer S, Kahn J, DeGruttola V, Crumpacker CS and Kuritzkes DR. Prevalence and clinical significance of Zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. 1995 J. Inf. Dis 171:1172-9.

Deeks S, Lalezari J, Pavia A, Rodriguez D, Drew L, Toole J, Jaffe H, Hellmann N, Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults. J Inf Dis 1996; 176: 1517-1523.

RW Coombs, SL Wells, Cooper C, D'Aquilla RT, Japour AJ, Johnson VA, Richman DD, Kuritzkes DR, Kwok S, Todd J, Jackson B, DeGrettola V, Crumpacker CS, Reichelderfer PS, and Kahn J. Association of plasma Human Immunodeficiency Virus Type-1 RNA level with risk of clinical progression in patients with advanced infection. J Inf Dis 1996; 174:704-12.

Wells SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton L, Johnson VA, Kuritzkes DR, D'Aquilla, Reichelderfer PA, Richman DD, Reichman R, Fischl MA, Dolin R, Coombs RW, Kahn J, McLaren C, Todd J, Kwok S, Crumpacker CS. Prognostic value of plasma Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Inf Dis 1996;174:696-703.

Chesney MA, Chamber DB, and Kahn J. Risk Behavior for HIV in Participants in Preventive HIV Vaccine Trials: A cautionary Note. JAIDS 1997; 16:266-271.

Deeks S, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-153.

Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn J. The safety, pharmacokinetic and antiretroviral activity of intravenous PMPA, a novel anti-HIV therapy, in HIV-infected adults. Anitmicrobial Agents and Chemotherapy 1998: 42:2380-84.

Hecht FM, Grant RM, Hellman N, Dillon B, Chesney MA, Bandrapalli NI, Petropoulos C, Goldstein M, Digillo L, Branson B, and Kahn J. Transmission of Human Immunodeficiency Virus Type-1 Resistant to Multiple Reverse Transcriptase and Protease Inhibitors. N Engl J Med 1998;339:307-11.

Janssen RS, Satten GA, Stramer SL, Rawal BD, OêBrien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn J, Chesney MA, Busch MP, a new testing strategy to diagnose early HIV-1 infection for estimating HIV-1 incidence and for clinical and prevention purposes. JAMA 1998;280:42-48.

Kahn J, and Walker BD. Acute Human Immunodeficiency Virus type-1 N Engl J Med.1998;339:33-40.

Kahn JO. Success and Sadness. In A Piece of My Mind. JAMA 1998;280:89.

Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, et al. Evolutionary pattern of Human Immunodeficiency Virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nature Medicine, 1998;4:341-5.

Henry WK, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH , Kenton A, Hirsch MS, Phair J, Marintez A and Kahn J for the AIDS Clinical Trial Group 193A study team JAIDS, 1998;19:339-49.

Locher CP, Grant RM, Collisson EA, Reyes-Teran G, Elbeik T, Kahn JO and Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV-1 gp 120 vaccination. AIDS Res and Human Retro, 1999 15:1685-9.

Kahn JO, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D,. Toole JJ, Coakley D for the GS-408 study team Efficacy and Safety of Adefovir Dipivoxil when added to Antiretroviral Therapy for the Treatment of HIV-1 Infected Patients with CD4+ T Cells Greater than 200 cells/mm3: A Multi-Center, Randomized, Double Blind, and Placebo-Controlled Study. JAMA 1999;282:2305-12.

Davey RT, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar Rl, Sahner DK, Duliege AM, Capra WB, Leong P, Giedlin MA, Lane HC and JO Kahn. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy. JAMA 2000; 284:183-9.

Kahn JO, Weng Cherng D, Mayer K, Murray H and Lagakos S for the 806 Investigator team. Evaluation of HIV-1 Immunogen, an Immunologic Modifier, administered to patients infected with HIV having 300 to 549 x 106?l CD4 cell counts. JAMA 2000:284:2193-2202.

Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A. 2001; 98(2):597-602.

Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. J Exp Med. 2001; 193:169-80.

Schito, Vittinghoff E, Hecht R, Elkins, Kahn J, Levy JA and Oksenberg J. Longitudinal analysis of T cell receptor gene usage by CD8+ T cells in early HIV infection in patients receiving highly active antiretroviral therapy. Blood 2001; 97:214-220.

Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M. Chambers D, Franses K, Coates TJ and Katz MH. Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP Study. J Inf Dis 2001; 183: 707-714.

S M Blower, A N Aschenbach, H B Gershengorn & JO Kahn Predicting the Unpredictable: the transmission of drug resistant HIV. Nat Med. 2001;7:1016-20.

Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C, van Der Horst C. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine. J Antimicrob Chemother. 2001; 48:507-513.

Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley SF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase 1/ll trial of the pharmacokinetics, safety and antiretroviral activity of tenofovir disoproxil fumurate in HIV- infected adults. Antimicrob Agents Chemother. 2001;45:2733-9.

Roland ME , Martin JD, Grant RM, Hellmann NS, Bamberger JD, Katz MH, Chesney M, Franses K, Coates TJ, and Kahn JO. Post-Exposure Prophylaxis for Human Immunodeficiency Virus Infection Following Sexual or Injection Drug Use Exposure: Identification and Characterization of the Source of Exposure J Inf Dis 2001;184:1608-12

1/4/02